{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Safety evaluated as number of participants with treatment-related adverse events as assessed by CTCAE v4.0.\n\nFrom date of first study drug to 30±3 days after the last dosing of the study drug or before the initiation of new cancer treatment.","groups":[{"description":"HBI-8000 Tablets","id":"OG000","title":"HBI-8000"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set (SAF) includes all subjects who received at least one dose of HBI 8000.","reportingStatus":"POSTED","timeFrame":"Up to approximately 44 months.","title":"Safety Evaluated as Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v.4.0","type":"SECONDARY","unitOfMeasure":"Participants"}